Participating Companies

Aardvark Therapeutics
Clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany fo­cused on the de­vel­op­ment and com­mer­cial­iza­tion of small molecule ther­a­peu­tics that ac­ti­vate in­nate home­o­stat­ic path­ways for the treat­ment of dis­ease. Lead prod­uct, ARD-101, is a first-in-class oral com­po­si­tion that is gut re­strict­ed, yet con­veys sys­temic ef­fects via ac­ti­va­tion of gut pep­tide hor­mone se­cre­tion. [more in­for­ma­tion]
Adiso Therapeutics inc
AD­S024 (SS-LBP) has just com­plet­ed a Phase 1b study for the pre­ven­tion of re­cur­rent CDI and will be un­der­tak­ing a Phase 2 study in mod­er­ate ul­cer­a­tive coli­tis (UC) this year. [more in­for­ma­tion]
Lead can­di­date Izok­ibep, sup­port­ed by part­n­er­ship with Ace­lyrin, is an IL-17 in­hibi­tor with mul­ti­ple Ph2 pro­grams in progress (PSO, axS­pA, uvei­tis, HS, PsA). ACR50 pri­mary end­point met for 16 wk da­ta in PsA. First pa­tient dosed in piv­o­tal Phase 2b trial for uvei­tis filed in 1H2022 with 24 wk da­ta ex­pect­ed in 2023. On­go­ing re­la­tion­ship with In­ma­gene in Chi­na. [more in­for­ma­tion]
AgomAb Therapeutics
The com­pany’s lead drug can­di­date, AGMB-129, is a gas­troin­testi­nal tract-re­strict­ed oral ALK-5 in­hibi­tor in de­vel­op­ment for the treat­ment of fi­brostenot­ic Crohn’s dis­ease and is cur­rent­ly in fi­nal stages of a Phase 1 clin­i­cal trial. [more in­for­ma­tion]
De­vel­op­ing a po­ten­tial­ly best-in-class oral im­munother­a­py that ad­dress­es a broad range of food al­ler­gies. AD­P101, which is in a Ph 1/2 study and an OLE study, is de­signed to de­sen­si­tize pa­tients al­ler­g­ic to one or to mul­ti­ple foods si­mul­ta­ne­ous­ly to miti­gate the risk of se­vere, life-threat­en­ing al­ler­g­ic re­ac­tions. The Com­pany was co-found­ed by Dr. Kari Nadeau, a renowned food al­ler­gist, and former 23andMe ex­ec, Ash­ley Dom­bkows­ki who serves is CEO. Da­ta from Ph 1/2 study ex­pect­ed 1Q23. [more in­for­ma­tion]
Arbor Biotechnologies
As the Com­pany cont­in­ues to ad­vance its pipe­line to­ward the clin­ic with an ini­tial fo­cus in liv­er and CNS dis­ease, Ar­bor al­so se­cured sev­er­al part­n­er­ships around gene edit­ing and ex vi­vo cell ther­a­py pro­grams to broa­d­en the reach of its nov­el nu­clease tech­nol­o­gy. [more in­for­ma­tion]
Bexion Pharmaceuticals
A clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing a new gen­er­a­tion of bi­o­log­ic im­munother­a­py to treat Solid Tu­mor Can­cers and Che­mother­a­py In­duced Pe­ripher­al Neu­ro­pa­thy (CIPN). Bexion's lead as­set BXQ-350 ac­ti­vates Sphin­goloid Metabolism and has de­mon­s­trat­ed ex­cel­lent safe­ty and monother­a­py ben­e­fits across mul­ti­ple tu­mor types in its com­plet­ed adult and pe­di­a­tric Ph 1 study. Ph 2 study in CRC ex­pect­ed 4Q22. The Com­pany has $80M raised to date. [more in­for­ma­tion]
En­gi­neered bi­o­log­ics gen­er­at­ed by the Brick­Bio plat­form are driv­en by the broad­est toolk­it of bio­con­ju­ga­tion chemistries and ex­clu­sive Site-Se­lect Pan­el in a holis­tic pro­cess to gen­er­ate and iden­ti­fy the op­ti­mal con­ju­ga­tion site. [more in­for­ma­tion]
Caraway Therapeutics
Car­away Ther­a­peu­tics is a bio­phar­ma­ceu­ti­cal com­pany pur­su­ing nov­el ap­proach­es for the treat­ment of ge­net­i­cal­ly defined neu­rode­gen­er­a­tive and rare dis­eas­es. The Com­pany is a lead­er in the cutt­ing-edge sci­ence of ac­ti­vat­ing cel­lu­lar re­cy­cling pro­cess­es to clear tox­ic ma­te­rials and de­fec­tive cel­lu­lar com­po­nents by mo­d­u­lat­ing ly­so­so­mal func­tion. [more in­for­ma­tion]
Catamaran Bio
We are us­ing our TAIL­WIND™ plat­form, an in­te­grat­ed suite of tech­nolo­gies, to spe­cif­i­cal­ly ad­dress the end-to-end meth­ods of en­gi­neer­ing, pro­cess­ing and man­u­fac­tur­ing NK cells and rapid­ly ad­vance our pipe­line of CAR-NK cell ther­a­py pro­grams. [more in­for­ma­tion]
Celsius Therapeutics
Cel­sius Ther­a­peu­tics is a biotech­nol­o­gy com­pany that de­vel­ops pre­ci­sion medicines for can­cer and au­toim­mune dis­ease pa­tients. [more in­for­ma­tion]
De­vel­op­er of nov­el ther­a­peu­tics in­tend­ed to ad­vance new medicines for se­ri­ous neu­ro­log­i­cal dis­eas­es. [more in­for­ma­tion]
CoRegen Inc
is fo­cused on the use of gene reg­u­la­tors and the nu­cleus of im­mune cells to treat can­cer and high in­ten­si­ty chron­ic ill­ness­es. This ther­a­py is ef­fec­tive with com­plete and durable elim­i­na­tion of can­cer cells, safe with no signs of toxic­i­ty, no in­flam­ma­tion, re­tain­ing healthy metabolism, and pre­ven­tive of can­cer re­cur­rence. [more in­for­ma­tion]
DTx Pharma
De­vel­op­er of an RNA-based ther­a­peu­tics de­signed to aid in per­so­n­al­ized treat­ment across most ther­a­peu­tic ar­eas. The com­pany's tech­nol­o­gy en­ables ef­fi­cient de­liv­ery of nu­cle­ic acid drugs to tis­sues through­out the body, en­abling health­care providers to de­liv­er oli­gos in vi­vo at ther­a­peu­ti­cal­ly rel­e­vant dos­es that work in many cell types in­clud­ing neu­rons, en­dothe­lial and T cells. [more in­for­ma­tion]
Our tech­nol­o­gy has led to a set­up of a full fledge plat­form in­to which each com­po­nent is able to in­duce in pa­tients cross re­ac­tive ef­fec­tor me­m­o­ry T cells dom­i­nat­ing im­mune re­spons­es gen­er­at­ing from naive T cells, be­ing pre­sent at much high­er fre­quen­cy, easi­er to ac­ti­vate when hav­ing right anti­gens and keep­ing strong re­ac­tiv­i­ty against hu­man can­cer (no neg­a­tive thymic se­lec­tion). [more in­for­ma­tion]
Epic Bio
Epi­cris­pr Biotech­nolo­gies is a pre-clin­i­cal stage gene ther­a­py com­pany build­ing the world’s most ex­pan­sive ther­a­peu­tic pipe­line based on the emerg­ing sci­ence of epi­ge­net­ic en­gi­neer­ing. [more in­for­ma­tion]
Geneius Biotech­nol­o­gy en­ables per­so­n­al­ized medicine to trans­form can­cer ther­a­py by tar­get­ing mul­ti­ple can­cer driv­er mu­ta­tions with T cells that spe­cif­i­cal­ly kill can­cer cells (not nor­mal cells) and mod­i­fy the tu­mor mi­croen­vi­ron­ment across mul­ti­ple solid and he­ma­to­log­ic can­cers re­sult­ing in a molec­u­lar rather than a tis­sue-based prod­uct la­bel for the ther­a­py of can­cer. [more in­for­ma­tion]
hC Bioscience, Inc.
hC Bio­s­cience, Inc is an in­no­va­tor and pi­oneer of pro­tein edit­ing us­ing gene and con­text ag­nos­tic en­gi­neered tR­NA. The Com­pany's first in class ap­proach for pro­tein edit­ing ad­vances far be­yond genome edit­ing to the di­rect mod­i­fi­ca­tion of the pro­teome, lead­ing to more ac­cu­rate and ef­fi­cient gene ther­a­py treat­ment op­tions. [more in­for­ma­tion]
Imbria Pharmaceuticals
Im­bria Phar­ma­ceu­ti­cals, a biotech­nol­o­gy com­pany, de­vel­op­ing nov­el ther­a­pies de­signed to sub­s­tan­tial­ly im­prove the lives of pa­tients with life-al­ter­ing dis­eas­es, with lo­ca­tions in San Die­go, CA, and Bos­ton, MA [more in­for­ma­tion]
De­vel­op­er of a tech­nol­o­gy in­tend­ed to pro­vide treat­ments for on­col­o­gy and au­to-im­mune di­s­or­ders. The com­pany's tech­nol­o­gy com­bines bi­ol­o­gy with ma­chine-learn­ing to un­rav­el the im­mune sys­tem, en­abling clini­cians to com­pre­hen­sive­ly view and in­ter­ro­gate da­ta and de­rive nov­el con­clu­sions on the un­der­ly­ing mech­anisms of dis­ease. [more in­for­ma­tion]
A pri­vate, clin­i­cal stage ther­a­peu­tic in­nate im­mu­ni­ty com­pany de­vel­op­ing drugs tar­get­ing the cGAS-ST­ING path­way for the treat­ment of can­cer and au­toim­mune dis­eas­es. The com­pany was co-found­ed by Dr. Zhi­jian “James” Chen of UTSW who won the 2019 Break-through prize and 2018 Lurie prize for the dis­cov­ery of the cGAS-ST­ING path­way. The com­pany pipe­line in­cludes a clin­i­cal stage ST­ING ag­on­ist, cur­rent­ly in monother­a­py and ICI com­bi­na­tion trial, with ex­pec­ta­tions to en­ter Phase 2 in 2H23. [more in­for­ma­tion]
Im­vax™ is a clin­i­cal-stage biotech­nol­o­gy com­pany de­vel­op­ing per­so­n­al­ized, whole tu­mor-de­rived im­munother­a­pies. Im­vax’s im­munother­a­py plat­form is a mul­ti-step pro­cess de­signed to de­liv­er per­so­n­al­ized, whole tu­mor-de­rived im­munother­a­pies. [more in­for­ma­tion]
Indapta Therapeutics
The Com­pany most re­cent­ly raised over $50 mil­lion in Se­ries A fi­nanc­ing and com­mit­ments co-led by RA Cap­i­tal Man. [more in­for­ma­tion]
iOnc­tu­ra is a clin­i­cal-stage com­pany ap­p­ly­ing in­sights in can­cer bi­ol­o­gy to de­vel­op high­ly se­lec­tive drugs that can si­mul­ta­ne­ous­ly in­hib­it mul­ti­ple tu­mor sur­vi­val mech­anisms. iOnc­tu­ra’s drug de­vel­op­ment pro­grams com­bine im­mune-me­di­at­ed and di­rect an­ti-tu­mor ac­tiv­i­ty to de­liv­er molecules with su­pe­ri­or clin­i­cal ef­fi­ca­cy and safe­ty in on­col­o­gy. [more in­for­ma­tion]
Cre­at­ing the new gen­er­a­tion of bi­o­log­ics us­ing its plant-based plat­form that has de­mon­s­trat­ed an abil­i­ty to cre­ate po­ten­tial­ly bet­ter drug can­di­dates at a frac­tion of the time and cost of con­ven­tio­n­al plat­forms. Fo­cused on dis­cov­er­ing mon­o­clo­n­al anti­bodies tar­get­ing vali­dat­ed path­ways for rare and in­fec­tious dis­eas­es and, due to the speed and ac­cu­ra­cy of its anti­body pro­duc­tion sys­tem, is po­si­tioned well to de­vel­op fast fol­low­er ther­a­pies against vali­dat­ed drug tar­gets. [more in­for­ma­tion]
KisoJi Biotech Inc.
Ki­so­Ji is a lead­ing next-gen­er­a­tion anti­body com­pany de­vel­op­ing high­ly dif­fer­en­ti­at­ed ther­a­peu­tic anti­bodies with nov­el and/or mul­ti-spe­cif­ic func­tio­n­al­i­ty to ad­dress dif­fi­cult tar­gets in on­col­o­gy and other dis­eas­es. [more in­for­ma­tion]
LENZ [0910137D]
LENZ Ther­a­peu­tics is a late-stage clin­i­cal com­pany de­vel­op­ing in­no­va­tive oph­thalmic phar­ma­ceu­ti­cal prod­ucts that im­prove vi­sion. Their lead pro­gram is an ace­c­li­dine based eye drop de­signed to re­s­tore the loss of near vi­sion as­so­ci­at­ed with pres­by­opia. [more in­for­ma­tion]
MiNA Therapeutics
Lead­er in RNA ac­ti­va­tion (RNAa). Tech­nol­o­gy ca­pa­ble of drug­ging any pro­tein tar­get to in­crease na­t­u­ral pro­tein pro­duc­tion in pa­tients own cells. Im­muno-on­col­o­gy and rare dis­ease pipe­line with 10 clin­i­cal as­sets ex­pect­ed by 2025 and first FDA ap­pro­val in 2024. Key pro­grams in­clude MTL-CEP­BA (on­go­ing ran­domized Ph2 in 2L HCC, Ph1/1b in ad­vanced solid tu­mors re­sis­tant to an­ti-PD1), MTL-ST­ING, mono­gene­ic rare dis­ease pro­grams. $1.5B+ phar­ma part­n­er­ships. [more in­for­ma­tion]
Minerva Biotechnologies
A clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing can­cer im­munother­a­pies and drugs to tar­get 75% of solid tu­mors and to pre­vent can­cer me­tas­ta­sis. Min­er­va has a pipe­line that in­cludes next-gen CAR Ts and other mo­dal­i­ties. The Com­pany has an on­go­ing Phase I/II study of huM­NC2-CAR44, an au­tol­o­gous CAR T ther­a­py, tar­get­ing the tu­mor-as­so­ci­at­ed form of MUC1 (MUC1*) which is a growth fac­tor re­cep­tor that drives growth of an es­ti­mat­ed 93% of breast can­cers. [more in­for­ma­tion]
MISSION Therapeutics
Mis­sion Ther­a­peu­tics is de­vel­op­ing a rich pipe­line of first-in-class small molecule DUB in­hibi­tors for a num­ber of sig­ni­f­i­cant clin­i­cal in­di­ca­tions. [more in­for­ma­tion]
Model Medicines
Mod­el Medicines is a new type of soft­ware com­pany, com­bin­ing hu­man ex­per­tise and ma­chine learn­ing to ac­cel­er­ate the cre­a­tion of life-chang­ing Phase II/III ready drug can­di­dates in days rather than de­cades. [more in­for­ma­tion]
NodThera Limited
Op­er­a­tor of a clin­i­cal-stage biotech­nol­o­gy com­pany in­tend­ed to de­vel­op medicines to treat dis­eas­es driv­en by chron­ic in­flam­ma­tion. The com­pany is fo­cused on de­vel­op­ing a new class of po­tent and se­lec­tive NL­R­P3 in­flam­ma­some in­hibi­tors, pro­vid­ing med­i­cal prac­ti­tion­ers with tools to help pa­tients with vari­ous chron­ic dis­eas­es. [more in­for­ma­tion]
NorthSea Therapeutics
Fo­cused on de­vel­op­ing SE­FAs for the treat­ment of NASH and other metabolic di­s­or­ders. Phase 2b ICO­NA NASH trial icos­abu­tate showed sig­ni­f­i­cant de­creas­es in NASH and fi­brot­ic bio­mark­ers and is sche­d­uled to read­out biop­sy da­ta in 1Q23. Two ad­di­tio­n­al SE­FAs (1024 and 6179) in Phase 1 clin­i­cal trials for pa­tients with dys­lipi­demia and the or­phan in­di­ca­tion IFALD, re­spec­tive­ly. [more in­for­ma­tion]
Oli­gon Inc. is an emerg­ing biotech­nol­o­gy com­pany de­vel­op­ing a nov­el class of mul­ti­mo­dal RNA ther­a­peu­tics for the treat­ment of can­cer & other com­plex multi­genic dis­eas­es. heir pro­pri­e­tary SeekR™ plat­form is used to dig­i­tal­ly en­gi­neer and rapid­ly pro­duce self-de­liv­er­ing ther­a­peu­tics which tar­get spe­cif­ic tis­sues with un­prece­dent­ed pre­ci­sion and ac­cu­ra­cy. [more in­for­ma­tion]
Pipeline Therapeutics
Pipe­line Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany pi­oneer­ing the de­vel­op­ment and com­mer­cial­iza­tion of first-in-class ther­a­pies for pre­ci­sion neu­rore­gen­er­a­tion in­clud­ing myelin res­to­ra­tion, sy­nap­to­ge­n­e­sis and ax­o­n­al re­pair. The Com­pany has a broad pipe­line of pro­grams to ad­dress CNS con­di­tions. [more in­for­ma­tion]
Plex­i­um is the pre­mi­er, next-gen­er­a­tion Tar­get­ed Pro­tein Degra­da­tion (TPD) com­pany seek­ing to dis­cov­er a wide range of mono­va­lent tar­get pro­tein de­graders that ad­dress the lim­i­ta­tions of heter­ob­i­func­tio­n­al de­graders and cere­blon IMiDs. [more in­for­ma­tion]
Prile­nia is a clin­i­cal stage biotech com­pany, led by Michael Hay­den, MD, PhD., to­gether with a high­ly ex­pe­ri­enced team with a track re­cord of suc­cess. Michael is a world-renowned sci­en­tist in Hunt­ing­ton Dis­ease re­search. He is the former Presi­dent of Glob­al R&D and Chief Sci­en­tif­ic Of­fi­cer at Te­va Phar­ma­ceu­ti­cals, where he led the de­vel­op­ment of ~35 new prod­ucts to­wards ap­pro­val in sev­er­al ma­jor mar­kets, pre­dom­i­nant­ly in CNS. The com­pany has re­cent­ly raised $68.5M in a Se­ries A fi­nanc­ing round to launch [more in­for­ma­tion]
Prolacta Bioscience
Pro­lac­ta Bio­s­cience pro­vides hu­man milk-based nu­tri­tio­n­al prod­ucts for pre­ma­ture in­fants in the neo­na­tal in­ten­sive care unit (NICU). They are the world’s lead­ing hos­pi­tal provider of 100% hu­man milk–based nu­tri­tio­n­al prod­ucts, made from 100% donor milk in­stead of cow milk. [more in­for­ma­tion]
The Com­pany is sup­port­ed by a strong, in­ter­na­tio­n­al­ly renowned team who aim to har­ness the po­ten­tial of ge­nom­ic medicine to de­liv­er new treat­ments to all oc­u­lar dis­ease pa­tients as quick­ly as pos­si­ble. [more in­for­ma­tion]
Transition Bio
Tran­si­tion Bio is a mi­crofluidics-driv­en drug dis­cov­ery plat­form com­pany work­ing to estab­lish a one-of-a-kind tech­nol­o­gy plat­form us­ing cell imag­ing and ma­chine learn­ing to rev­o­lu­tion­ize con­den­sate drug dis­cov­ery. [more in­for­ma­tion]
Treos Bio
De­vel­ops pre­ci­sion pep­tide can­cer im­munother­a­pies us­ing pa­tient HLA tar­get recog­ni­tion ge­net­ics based on pro­pri­e­tary com­pu­ta­tio­n­al da­ta sci­ence. Tre­os’ lead can­di­date is Po­lyPEPI-1018, an off-the-shelf im­munother­a­py for the treat­ment of me­tastat­ic col­orec­tal can­cer cur­rent­ly in a bio­mark­er-based Phase 1b clin­i­cal trial. Tre­os has raised $42 mil­lion to date. [more in­for­ma­tion]
Tune Therapeutics
Tune Ther­a­peu­tics, Inc. is uti­l­iz­ing the epigenome to treat com­plex, per­va­sive dis­eas­es that have long elud­ed treat­ment. With its ver­satile and pow­er­ful TEM­PO epige­nom­ic con­trol plat­form, Tune’s ex­pe­ri­enced team is pi­oneer­ing a new ther­a­peu­tic mo­dal­i­ty that can fine-tune any gene net­work with­out break­ing or per­ma­nent­ly rewrit­ing DNA. [more in­for­ma­tion]
XyloCor Therapeutics
Xy­lo­Cor Ther­a­peu­tics is a bio-phar­ma­ceu­ti­cal com­pany de­vel­op­ing gene ther­a­py for peo­ple with ad­vanced coro­nary artery dis­ease. It's lead drug can­di­date, XC001, is cur­rent­ly in Phase 2 with re­sults re­port­ing out in 2022 and 2023. Promis­ing Phase 1 re­sults were pre­sent­ed ear­li­er this year. [more in­for­ma­tion]